Publications by authors named "W Yamamoto"
Background: This study investigated poor prognostic factors for the relapse of interstitial lung disease (ILD) in patients with microscopic polyangiitis (MPA) after remission induction therapy.
Methods: We enrolled patients diagnosed with MPA complicated by ILD according to the Chapel Hill Consensus definition from 2001 to 2023 in multiple institutions in the REVEAL cohort. All patients who were treated with immunosuppressive therapy were followed up, and those who relapsed with ILD were extracted in this study.
Introduction: Favipiravir is a known anti-influenza agent that has been used globally, especially during the coronavirus disease 2019 (COVID-19) pandemic. This drug has been important for treating influenza and other emerging infectious diseases, although it was ultimately proven to be ineffective for COVID-19. Currently, no studies have reported the human-milk transfer of favipiravir at doses of 1,600-3,600 mg/day in the treatment of diseases, including COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates how different biological and targeted synthetic anti-rheumatic drugs (b/tsDMARDs) affect kidney function in patients with rheumatoid arthritis (RA), particularly focusing on the incidence of chronic kidney disease (CKD).
- - Researchers followed 2,187 patients and evaluated the effects of tumor necrosis factor inhibitors (TNFi), cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig), interleukin-6 receptor inhibitors (IL-6Ri), and Janus kinase inhibitors (JAKi) on kidney health. They found that TNFi was linked to a lower CKD risk, while JAKi was associated with a higher risk.
- - The findings suggest that
Article Synopsis
- * Twenty-seven young men participated, undergoing tests for peak work rate, oxygen uptake, muscle strength, mass, quality, and oxygen extraction rate.
- * Results showed that muscle oxygen extraction rate (MOER) is significantly linked to aerobic capacity, making it a valuable measure that isn't influenced by body weight.
Background: Mepolizumab (MPZ) has demonstrated efficacy in clinical trials for eosinophilic granulomatosis with polyangiitis (EGPA); however, few studies compare the disease course between patients treated with MPZ (MPZ group) and those who were not treated with MPZ (non-MPZ group) in real-world settings.
Objectives: This study aimed to compare the disease course and outcomes between the two groups and assess the long-term efficacy of MPZ in a multicenter cohort in Japan. Methods: We enrolled 113 EGPA patients registered in the cohort until June 2023.